Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
Adv Ther
.
2017 Jan;34(1):277-279.
doi: 10.1007/s12325-016-0442-2.
Authors
Mustapha Tehfe
1
,
Scot Dowden
2
,
Hagen Kennecke
3
,
Robert El-Maraghi
4
,
Bernard Lesperance
5
,
Felix Couture
6
,
Richard Letourneau
7
,
Helen Liu
8
,
Alfredo Romano
8
Affiliations
1
Centre hospitalier de l'université de Montréal (CHUM), Montreal, QC, Canada. mustapha.tehfe.chum@ssss.gouv.qc.ca.
2
Tom Baker Cancer Centre, Calgary, AB, Canada.
3
British Columbia Cancer Agency, Vancouver, BC, Canada.
4
Royal Victoria Regional Health Centre, Barrie, ON, Canada.
5
Hôpital du Sacré-Coeur de Montreal, Montreal, QC, Canada.
6
Centre hospitalier universitaire de Québec (CHUQ), Hôtel-Dieu de Quebec, CHUM, Montreal, QC, Canada.
7
Centre hospitalier de l'université de Montréal (CHUM), Montreal, QC, Canada.
8
Celgene Corporation, Summit, NJ, USA.
PMID:
27885491
PMCID:
PMC5216084
DOI:
10.1007/s12325-016-0442-2
No abstract available
Publication types
Published Erratum